Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of N-Rephasin SAL200 in Healthy Volunteers
NCT03446053Phase 1Completed
- Sponsor
- iNtRON Biotechnology
- Start
- Feb 2018
- Primary completion
- Feb 2019
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Staphylococcus aureus infection comparing N-Rephasin SAL200 with Placebo (2 arms). Primary endpoint: Safety and Tolerability Evaluation up to 50 days. Started Feb 2018; status: completed.
02
Drugs
tonabacase
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT03446053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446053.